1.Giuseppe Curigliano, et al. Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy...
Modified bullet: Randomized trials have shown that ovarian suppression with GnRH agonist therapy administered during adjuvant chemotherapy in premenopausal women with breast tumors (regardless of hormone receptor status), ER-negative tumors may preserve ovarian function and diminish the likelihood of chemother...
Hormone receptor status of breast cancer in India: a study of 798 tumours. The Breast 2000;9:267-70.Desai SB, Moonim MT, Gill AK, Punia RS, Naresh KN, Chinoy RF. Hormone receptor status of breast cancer in India: A study of 789 tumours. Breast 2000;9:267-70....
and three cell lines with hormone receptor status patterns corresponding to luminal A tumors. Importantly, regarding the HER2-positive cell lines included in our study (initial: BT-474; additional: ZR-75-30); these cell lines are hormone receptor positive and have luminal characteristics, and belo...
Worldwide, many patients with HER2+ (human epidermal growth factor receptor 2-positive) early breast cancer (BC) do not receive adjuvant trastuzumab. Hazards of recurrence of these patients with respect to hormone receptor status of the primary tumor have not been described. Methods Using data fro...
requires yearly ER, PR, and Her-2 immunostaining results [11]. Moreover, due to the possible value of the hormone receptor expression status on the prediction of local recurrence [12], statistics of hormone receptor expression status is also valuable for research on recurrent breast cancer. ...
Based on these findings, we hypothesized that TGFβ is a key regulator of proliferation and pool size of hormone-responsive mammary epithelial progenitors that may serve as the cell-of-origin of breast cancer, and that decreasing these progenitors could reduce the rate of mammary tumor initiation....
(T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06...
[9] P. Schmid, J. Cortés, F. Marmé,Tet al; 214MO - Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 stud...